IMMURON ORD
Market wrap: big banks send ASX into record territory
Australia’s big banks have pushed the ASX 200 to a record close of 7847 points after more signs of lower inflation in major economies caused a global relief rally. With interest rates now looking almost a certainty to fall in the big markets of the US, Europe and Australia, investors celebrated hard with a fresh […]
Immuron’s Travelan study results show major leap in digestive health protection, plans Phase 3 trial
Australian biopharmaceutical company Immuron (ASX: IMC) has released interim topline results from a US-based clinical trial of lead candidate IMM-124E (Travelan) confirming that a single daily dose can be effective in the prevention of moderate-to-severe diarrhea caused by enterotoxigenic Escherichia coli (ETEC). The double-blind, phase 2 controlled human infection model trial aimed to evaluate a […]
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19. IMM-124E is used in Immuron’s over-the-counter Travelan and Protectyn products which were developed as immunotherapeutics to prevent travellers’ diarrhea and other gastrointestinal and digestive issues. The products are commercially available, with […]
Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND meeting with the US Food and Drug administration (FDA). Immuron and the NMRC could potentially see developmental progress made, despite […]
